Lode HN - Search Results

1

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.

Seidel D, Shibina A, Siebert N, Wels WS, Reynolds CP, Huebener N, Lode HN. Seidel D, et al. Among authors: lode hn. Cancer Immunol Immunother. 2015 May;64(5):621-34. doi: 10.1007/s00262-015-1669-5. Epub 2015 Feb 25. Cancer Immunol Immunother. 2015. PMID: 25711293 Free PMC article.

2

Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia.

Schroeder U, Bernt KM, Lange B, Wenkel J, Jikai J, Shabat D, Amir R, Huebener N, Niethammer AG, Hagemeier C, Wiebusch L, Gaedicke G, Wrasidlo W, Reisfeld RA, Lode HN. Schroeder U, et al. Among authors: lode hn. Blood. 2003 Jul 1;102(1):246-53. doi: 10.1182/blood-2002-07-2268. Epub 2003 Mar 6. Blood. 2003. PMID: 12623853 Free article.

3

AACR Special Conference in cancer research: ubiquitination in normal and cancer cells.

Huebener N, Lode HN. Huebener N, et al. Among authors: lode hn. Expert Opin Biol Ther. 2003 Feb;3(1):187-92. doi: 10.1517/14712598.3.1.187. Expert Opin Biol Ther. 2003. PMID: 12718741

4

Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma.

Huebener N, Lange B, Lemmel C, Rammensee HG, Strandsby A, Wenkel J, Jikai J, Zeng Y, Gaedicke G, Lode HN. Huebener N, et al. Among authors: lode hn. Cancer Lett. 2003 Jul 18;197(1-2):211-7. doi: 10.1016/s0304-3835(03)00102-2. Cancer Lett. 2003. PMID: 12880984

5

Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase.

Jikai J, Shamis M, Huebener N, Schroeder U, Wrasidlo W, Wenkel J, Lange B, Gaedicke G, Shabat D, Lode HN. Jikai J, et al. Among authors: lode hn. Cancer Lett. 2003 Jul 18;197(1-2):219-24. doi: 10.1016/s0304-3835(03)00104-6. Cancer Lett. 2003. PMID: 12880985

6

Rationally designed hydrolytically activated etoposide prodrugs, a novel strategy for the treatment of neuroblastoma.

Lange B, Schroeder U, Huebener N, Jikai J, Wenkel J, Strandsby A, Wrasidlo W, Gaedicke G, Lode HN. Lange B, et al. Among authors: lode hn. Cancer Lett. 2003 Jul 18;197(1-2):225-30. doi: 10.1016/s0304-3835(03)00106-x. Cancer Lett. 2003. PMID: 12880986

7

DNA minigene vaccination for adjuvant neuroblastoma therapy.

Lode HN, Huebener N, Zeng Y, Fest S, Weixler S, Gaedicke G. Lode HN, et al. Ann N Y Acad Sci. 2004 Dec;1028:113-21. doi: 10.1196/annals.1322.012. Ann N Y Acad Sci. 2004. PMID: 15650237 Review.

8

Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.

Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, Lewis G, Ladenstein R, Lode HN. Zeng Y, et al. Among authors: lode hn. Mol Immunol. 2005 Jul;42(11):1311-9. doi: 10.1016/j.molimm.2004.12.018. Epub 2005 Apr 7. Mol Immunol. 2005. PMID: 15950727

9

Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2.

Zeng Y, Jiang J, Huebener N, Wenkel J, Gaedicke G, Xiang R, Lode HN. Zeng Y, et al. Among authors: lode hn. Cancer Lett. 2005 Oct 18;228(1-2):187-93. doi: 10.1016/j.canlet.2005.01.057. Cancer Lett. 2005. PMID: 15953676 Review.

10

Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases.

Fest S, Huebener N, Weixler S, Bleeke M, Zeng Y, Strandsby A, Volkmer-Engert R, Landgraf C, Gaedicke G, Riemer AB, Michalsky E, Jaeger IS, Preissner R, Förster-Wald E, Jensen-Jarolim E, Lode HN. Fest S, et al. Among authors: lode hn. Cancer Res. 2006 Nov 1;66(21):10567-75. doi: 10.1158/0008-5472.CAN-06-1158. Cancer Res. 2006. PMID: 17079481

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

148 results

Search Page

Filters